NASDAQ: ADMA

Adma Biologics Inc Stock Forecast, Predictions & Price Target

The consensus among 3 Wall Street analysts covering (NASDAQ: ADMA) stock is to Strong Buy ADMA stock.

Out of 3 analysts, 2 (66.67%) are recommending ADMA as a Strong Buy, 1 (33.33%) are recommending ADMA as a Buy, 0 (0%) are recommending ADMA as a Hold, 0 (0%) are recommending ADMA as a Sell, and 0 (0%) are recommending ADMA as a Strong Sell.

If you're new to stock investing, here's how to buy Adma Biologics stock.

(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 19.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Adma Biologics's revenue in 2024 is $258,215,000.On average, 2 Wall Street analysts forecast ADMA's revenue for 2024 to be $76,613,533,225, with the lowest ADMA revenue forecast at $76,316,846,918, and the highest ADMA revenue forecast at $76,910,219,532. On average, 2 Wall Street analysts forecast ADMA's revenue for 2025 to be $89,062,947,099, with the lowest ADMA revenue forecast at $89,005,892,040, and the highest ADMA revenue forecast at $89,120,002,158.

In 2026, ADMA is forecast to generate $101,033,098,477 in revenue, with the lowest revenue forecast at $101,033,098,477 and the highest revenue forecast at $101,033,098,477.

According to 3 Wall Street analysts that have issued a 1 year ADMA price target, the average ADMA price target is $8.50, with the highest ADMA stock price forecast at $10.00 and the lowest ADMA stock price forecast at $7.50.

On average, Wall Street analysts predict that Adma Biologics's share price could reach $8.50 by Mar 26, 2025. The average Adma Biologics stock price prediction forecasts a potential upside of 37.1% from the current ADMA share price of $6.20.

(NASDAQ: ADMA) forecast ROE is N/A, which is considered weak.